T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis, and paralysis. The progress made in more than one decade of research in animal models of MS for clarifying the pathophysiology of MS disease validated the concept that MS is an autoimmune inflammatory disorder caused by the recruitment in the CNS of self-reactive lymphocytes, mainly CD4+ T cells. Indeed, high levels of T helper (Th) cells and related cytokines and chemokines have been found in CNS lesions and in cerebrospinal fluid (CSF) of MS patients, thus contributing to the breakdown of the blood–brain barrier (BBB), the activation of resident astrocytes and microglia, and finally the outcome of neuroinflammation. To date, several types of Th cells have been discovered and designated according to the secreted lineage-defining cytokines. Interestingly, Th1, Th17, Th1-like Th17, Th9, and Th22 have been associated with MS. In this review, we discuss the role and interplay of different Th cell subpopulations and their lineage-defining cytokines in modulating the inflammatory responses in MS and the approved as well as the novel therapeutic approaches targeting T lymphocytes in the treatment of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 1×
“Multiple sclerosis (MS) is a chronic inflammatory autoimmune disorder of the central nervous system (CNS) affecting about 2–3 million people worldwide that is triggered by both environmental and genetic factors [1,2].”
BackgroundFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“In the last two decades, progress has been made to better characterize Treg cells in the context of autoimmune diseases and at least two main subsets of CD4+ Treg cells have been identified: natural nTreg cells that develop in the thymus following the recognition of self-antigens and express the transcription factor f…”
BackgroundBettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“In the mouse system, the differentiation of Th17 cells is promoted by TGFβ in combination with either IL-6 or IL-21 or IL-1β [82,83].”
BackgroundSakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 1×
“In particular, IL-17A and IL-17F act on several cell types like macrophages, epithelial, and endothelial cells by inducing the expression of inflammatory cytokines and chemokines and promoting the recruitment of neutrophils in inflammatory sites [47,48].”
BackgroundHarrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 2×
“Th17 cells have been identified in 2005 [41] as an important subset of CD4+ Th cells that mediates efficient immune responses against extracellular bacteria and fungi [44].”
BackgroundA Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 2×
“IL-21 provides a positive-feedback loop for successful amplification of the Th17 cell subset [49], and IL-22 acts on epithelial cells favoring the production of antimicrobial peptides and mucus [50].”
BackgroundImmunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 1×
“recently reported that ocrelizumab, a humanized mAb targeting CD20 approved in 2017 for relapsing MS and PPMS and thought to specifically target B cells [206,207], was also effective in depleting a highly activated CD20+ T cell subset producing inflammatory cytokines [208].”
BackgroundSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“In particular, Secukinumab, a fully humanized anti-IL17A mAb aimed at suppressing pathogenic Th17 and Th1-like Th17 cell subset, has been approved in 2005 as first-line therapy for psoriasis [211,212].”
BackgroundOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 1×
“recently reported that ocrelizumab, a humanized mAb targeting CD20 approved in 2017 for relapsing MS and PPMS and thought to specifically target B cells [206,207], was also effective in depleting a highly activated CD20+ T cell subset producing inflammatory cytokines [208].”
BackgroundAcosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828 · cited 1×
“Recently, a novel Th1 cell subset known as Th1-like Th17 cells that produce both IFN-γ and IL-17 has been identified in both human and mice [111,112].”
BackgroundKebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 3×
“IL-17A in combination with IL-6 has been also described to promote the breakdown of BBB in RRMS patients [71] by altering the expression of adhesion molecules on endothelial cells [72,73] and favoring the depolymerization of the actin cytoskeleton near the tight junctions [74].”
BackgroundMultiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“The pathological hallmarks of MS are the breakdown of the blood–brain barrier (BBB), oligodendrocyte loss, demyelination, astrocytes gliosis, and axonal degeneration [6,7].”
BackgroundT Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ
Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.016 · Cited by 1,605
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells
Nurieva, R., Yang, X. O., Martinez, G., Zhang, Y., Panopoulos, A. D., Ma, L., Schluns, K., Tian, Q., Watowich, S. S., Jetten, A. M., et al. (2007) · Nature · doi:10.1038/nature05969 · Cited by 1,466
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R. A., Mitsdoerffer, M., Strom, T. B., Elyaman, W., Ho, I.-C., et al. (2008) · Nature Immunology · doi:10.1038/ni.1677 · Cited by 1,122
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells
Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1767 · Cited by 1,079
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“These data together with the initial findings that the administration of IFN-γ to MS patients exacerbated disease [30,31] supported an important role of IL-12/IFN-γ axis and Th1 cells in both EAE and MS pathogenesis.”
ResultProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 1×
“In about 15% of patients, MS is progressive from the onset and is called primary progressive (PP)MS, a clinical course characterized by a gradual and constant decline in neurological functions [5].”
BackgroundTrifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K., & Spits, H. (2009) · Nature Immunology · doi:10.1038/ni.1770 · Cited by 1,021
Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S. I., Hupé, P., Barillot, E., & Soumelis, V. (2008) · Nature Immunology · doi:10.1038/ni.1613 · Cited by 938
Self-citationJäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E., & Kuchroo, V. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901906 · Cited by 783 · cited 1×
“The results revealed that Th9 cell recipients possessed fewer infiltrates of lymphocytes in the meninges compared to EAE developed by Th1 and Th17 cells, thus suggesting that the mechanisms of EAE induction by Th9 cells differed from the mechanisms of Th1 and Th17 cells [142].”
ResultApetoh, L., Quintana, F. J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E. J., Sherr, D. H., Weiner, H. L., & Kuchroo, V. K. (2010) · Nature Immunology · doi:10.1038/ni.1912 · Cited by 725
Diagnosis of multiple sclerosis: progress and challenges
Brownlee, W. J., Hardy, T. A., Fazekas, F., & Miller, D. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30959-x · Cited by 701
Preferential recruitment of interferon‐γ–expressing T H 17 cells in multiple sclerosis
Kebir, H., Ifergan, I., Alvarez, J. I., Bernard, M., Poirier, J., Arbour, N., Duquette, P., & Prat, A. (2009) · Annals of Neurology · doi:10.1002/ana.21748 · Cited by 551 · cited 1×
“For instance, Th1-like Th17 cells were capable to cross the BBB and accumulate in the CNS of acute EAE and were also found in brain tissues from MS patients [119] and upregulated in RRMS patients during relapse [120].”
BackgroundElyaman, W., Bradshaw, E. M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.-C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812530106 · Cited by 498
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment
Nistala, K., Adams, S., Cambrook, H., Ursu, S., Olivito, B., de Jager, W., Evans, J. G., Cimaz, R., Bajaj-Elliott, M., & Wedderburn, L. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003852107 · Cited by 443
IL-9 as a mediator of Th17-driven inflammatory disease
Nowak, E. C., Weaver, C. T., Turner, H., Begum-Haque, S., Becher, B., Schreiner, B., Coyle, A. J., Kasper, L. H., & Noelle, R. J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090246 · Cited by 393
Heterogeneity of Human CD4 + T Cells Against Microbes
Sallusto, F. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112056 · Cited by 336 · cited 9×
“The results revealed that Th9 cell recipients possessed fewer infiltrates of lymphocytes in the meninges compared to EAE developed by Th1 and Th17 cells, thus suggesting that the mechanisms of EAE induction by Th9 cells differed from the mechanisms of Th1 and Th17 cells [142].”
BackgroundInfluentialKang, Z., Altuntas, C. Z., Gulen, M. F., Liu, C., Giltiay, N., Qin, H., Liu, L., Qian, W., Ransohoff, R. M., Bergmann, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.004 · Cited by 297 · cited 1×
“IL-17 has been described to upregulate the production of inflammatory cytokines and chemokines [57], and the impairment of IL-17-mediated signaling in astrocytes has been described to ameliorate EAE [58].”
BackgroundBrambilla, R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01980-7 · Cited by 246
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Paroni, M., Maltese, V., De Simone, M., Ranzani, V., Larghi, P., Fenoglio, C., Pietroboni, A. M., De Riz, M. A., Crosti, M. C., Maglie, S., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.045 · Cited by 77
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Cited by
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Repositioning TH cell polarization from single cytokines to complex help
Tuzlak, S., Dejean, A. S., Iannacone, M., Quintana, F. J., Waisman, A., Ginhoux, F., Korn, T., & Becher, B. (2021) · Nature Immunology · doi:10.1038/s41590-021-01009-w · Cited by 171
Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review
Berjaoui, C., Kachouh, C., Joumaa, S., Hussein Ghayyad, M., Abate Bekele, B., Ajirenike, R., Al Maaz, Z., Awde, S., Wojtara, M., Nazir, A., et al. (2024) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000002231 · Cited by 4
“Several varieties of Th cells are linked, such as Th1, Th17, Th1-like Th17, Th9, and Th22 [32] .”
Background
Metadata
- Authors
- Kunkl, M., Frascolla, S., Amormino, C., Volpe, E., & Tuosto, L.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-02-19
- Volume
- 9
- Issue
- 2
- Pages
- 482
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3008780596
- Cited by
- 232
- References
- 45
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.